Real-Time Artificial Intelligence Diagnostic Copilot in Simulated Primary Care Consultations: Randomized Simulation Study.

JMIR Form ResSep 22, 2026 (epub)
Clinical ResearchFamily Medicine

Ivan Cusacovich, Manuel Pinilla, Ruben Garcia Castro

✦ AI-curated · Sources linked

In 30 seconds

This randomized simulation study evaluated the impact of a real-time, voice-based AI diagnostic assistant on physician diagnostic accuracy in primary care consultations. Involving 13 board-certified physicians managing 260 simulated cases, the AI-assisted condition achieved a Top-3 diagnostic accuracy of 74.6% compared to 62.3% in the unassisted condition, with an adjusted odds ratio of 2.68 (P = .01).

Key findings

  • AI-assisted diagnostic accuracy was 74.6% compared to 62.3% in the unassisted condition.
  • The adjusted odds ratio for improved accuracy with AI assistance was 2.68 (P = .01).
  • Mean consultation time increased by 10.7% with AI assistance.
  • Physicians rated the AI system highly for usefulness and satisfaction.

Why it matters

The study highlights the potential of AI diagnostic assistants to enhance diagnostic accuracy in primary care, addressing a significant source of diagnostic errors. Understanding their effectiveness and risks is crucial for future clinical implementation.

Source

PubMed · PMID 42771885

Published in JMIR Form Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Family Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.